Barcelona SME specialising in computational toxicology, drug safety data integration, and next-generation chemical risk assessment for pharma and regulatory clients.
MedBioinformatics Solutions is a Barcelona-based biomedical informatics SME specialising in computational toxicology — the use of software models, data integration, and bioinformatics methods to predict how chemicals and drugs affect human health. Their work sits at the intersection of regulatory science and data engineering: they build and apply predictive models that connect pre-clinical safety data to human risk assessment, replacing or reducing reliance on animal testing. In the eTRANSAFE project they focused on making drug safety data interoperable across pharmaceutical companies, while in RISK-HUNT3R they moved into environmental chemical risk assessment using next-generation toxicology methods. Their commercial value lies in helping pharmaceutical and regulatory clients turn complex biological data into defensible safety decisions.
Both eTRANSAFE and RISK-HUNT3R rely on computational models for predicting drug and chemical toxicity, with keywords spanning read-across, AOP networks, toxicokinetics, and toxicodynamics.
eTRANSAFE (2017–2023) explicitly addressed SEND data standards, data sharing, and data interoperability for pre-clinical pharmaceutical safety datasets.
RISK-HUNT3R (2021–2026) directly applies human-centric next-generation testing strategies including exposure modelling, systems toxicology, and AOP-based frameworks for regulatory acceptance.
AOP appears in both projects — as a foundational concept in eTRANSAFE and as quantitative AOP networks in RISK-HUNT3R, showing growing depth in this area.
RISK-HUNT3R explicitly targets regulatory acceptance of new approach methodologies, indicating MedBioinformatics is positioning toward the policy-facing side of toxicology.
MedBioinformatics entered H2020 through pharmaceutical drug safety, working on the technical problem of making pre-clinical data (SEND format, data sharing, interoperability) usable across organisations — essentially data infrastructure for the pharma safety pipeline. By 2021 their focus had shifted from data plumbing toward the science itself: exposure modelling, toxicokinetics, toxicodynamics, and systems toxicology, applied to environmental chemicals rather than just drugs. The trajectory is clear: they started as data integration specialists within pharma safety and are evolving into a full-spectrum computational toxicology consultancy with regulatory ambitions.
MedBioinformatics is moving from pharmaceutical data infrastructure toward regulatory-grade computational risk assessment for environmental chemicals — making them increasingly relevant to chemical industry clients, environmental regulators, and REACH-compliance workflows.
MedBioinformatics has participated only as a consortium member, never as coordinator, across both projects — consistent with an SME that provides a specialised technical service within larger research programmes rather than leading them. Their average funding per project (~€370k) is modest, suggesting a focused contributor role rather than a work-package lead. With 61 unique partners across just 2 projects they operate inside very large international consortia, which is typical for ambitious RIA projects in computational health science.
MedBioinformatics has built a network of 61 unique partners spanning 13 countries through just two projects, reflecting the large multinational consortia typical of EU health RIAs. Their European reach includes collaborators from across multiple pharmaceutical, academic, and regulatory sectors.
MedBioinformatics occupies a rare niche: a private SME (not a university or large pharma) that delivers computational toxicology expertise at the intersection of bioinformatics, data standards, and regulatory science. Most organisations in this space are either academic groups or large CROs — MedBioinformatics offers the agility of an SME with a publication-grade scientific profile. Their dual experience in pharmaceutical safety (eTRANSAFE) and environmental chemical risk (RISK-HUNT3R) gives them cross-domain credibility that is uncommon at this company size.
